Biomarker
Cytotoxic t lymphocyte associated protein 4 (CTLA-4), also known as CD152, is a protein receptor continuously expressed in regulatory T cells. The main function of CTLA-4 is to downregulate immune responses. The anti-CTLA-4 blocking antibody ipilimumab was the first immune checkpoint inhibitor to be tested and approved for the treatment of cancer patients.